| Serial Number | 79376166 |
| Word Mark | LENTINEXT |
| Filing Date | Thursday, June 22, 2023 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, September 24, 2024 |
| Registration Number | 7510377 |
| Registration Date | Tuesday, September 24, 2024 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 9, 2024 |
| Goods and Services | Gene transfer agents for preventing and treating human vector-borne diseases; biological preparations, namely, biological vectors for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); biological preparations, namely, biological recombinant vectors for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); biological preparations for gene recombination for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); nucleic acids for medical, medicinal or veterinary purposes; biopharmaceuticals for the treatment of auto-immune diseases; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; reagents for use in medical genetic testing; pharmaceutical preparations for gene therapy and diagnosis of auto-immune diseases and cancer; pharmaceutical preparations for the diagnosis and the treatment of auto-immune diseases; anti-cancer preparations; antibiotics; anti-viral agents; anti-infectives; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cancer cells; cells for medical purposes |
| Pseudo Mark | LENTI NEXT |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, August 11, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | BioDesign Lab Co., Ltd. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | BioDesign Lab Co., Ltd. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | BioDesign Lab Co., Ltd. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Event Date | Event Description |
| Friday, August 11, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, August 15, 2023 | APPLICATION FILING RECEIPT MAILED |
| Thursday, August 10, 2023 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Monday, March 11, 2024 | ASSIGNED TO EXAMINER |
| Friday, March 15, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, April 3, 2024 | REFUSAL PROCESSED BY MPU |
| Saturday, March 16, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, May 9, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, April 3, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, April 23, 2024 | REFUSAL PROCESSED BY IB |
| Thursday, May 9, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, May 9, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, May 30, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, May 30, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, May 30, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, May 30, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, May 30, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, June 19, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, July 9, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, July 9, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 24, 2024 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, September 24, 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |